Pharmacokinetic study of omacetaxine mepesuccinate administered subcutaneously to patients with advanced solid and hematologic tumors

Cancer Chemotherapy and Pharmacology

Volumn 71, Issue 1, 2013, Pages 35-41

  Nemunaitis, John ^a   Mita, Alain ^b   Stephenson, Joe ^c   Mita, Monica M ^b   Sarantopoulos, John ^b   Padmanabhan Iyer, Swami ^b   Nanda, Nisha ^d   Gleich, Lyon ^e   Benichou, Annie Claude ^f   Craig, Adam ^e  

^a Mary Crowley Cancer Research Centers   (United States)

^b CTRC Institute for Drug Development   (United States)

^c Cancer Centers of the Carolinas   (United States)

^d ChemGenex Pharmaceuticals   (United States)

^e Medpace ^*  (United States)

^f Stragen Services SAS   (France)

Author keywords

Cephalotaxine; Homoharringtonine; Omacetaxine mepesuccinate; Phase 1; Subcutaneous

Indexed keywords

CEPHALOTAXINE; DRUG METABOLITE; HOMOHARRINGTONINE;

ABDOMINAL PAIN; ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; AREA UNDER THE CURVE; ARTICLE; CANCER GROWTH; CHEMOTHERAPY INDUCED NAUSEA AND VOMITING; CHRONIC MYELOID LEUKEMIA; CLINICAL ARTICLE; CLINICAL ASSESSMENT; COLON CANCER; CONSTIPATION; DEHYDRATION; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG EFFECT; DRUG ELIMINATION; DRUG EXCRETION; DRUG HALF LIFE; DRUG RESPONSE; DRUG SAFETY; DRUG URINE LEVEL; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOMAGNESEMIA; HYPONATREMIA; INJECTION SITE ERYTHEMA; LARGE CELL LYMPHOMA; LEUKOPENIA; LIVER CELL CARCINOMA; LUNG CANCER; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; PANCREAS CANCER; PAROTID GLAND CANCER; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; PROSTATE CANCER; QT PROLONGATION; RECURRENT CANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STEADY STATE; THROMBOCYTOPENIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; UTERINE CERVIX CANCER;

ADULT; AGED; ANTINEOPLASTIC AGENTS, PHYTOGENIC; FEMALE; HALF-LIFE; HARRINGTONINES; HEMATOLOGIC NEOPLASMS; HUMANS; INJECTIONS, SUBCUTANEOUS; LONG QT SYNDROME; MALE; MIDDLE AGED; NEOPLASMS; NEUTROPENIA; THROMBOCYTOPENIA; TISSUE DISTRIBUTION;

EID: 84872358218     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-012-1963-2     Document Type: Article

References (27)

1. Powell RG, Weisleder D, Smith CR Jr (1972) Antitumor alkaloids for Cephalataxus harringtonia: structure and activity. J Pharm Sci 61:1227-1230
2. Robin JP, Dhal R, Dujardin G, Girodier L, Mevellec L, Poutot S (1999) The first semisynthesis of enantiopure homoharringtonine via anhydrohomoharringtonine from a preformed chiral acyl moiety. Tetrahedron Lett 40:2931-2934
3. Legha SS, Keating M, Picket S, Ajani JA, Ewer M, Bodey GP (1984) Phase I clinical investigation of homoharringtonine. Cancer Treat Rep 68:1085-1091
4. Neidhart JA, Young DC, Derocher D, Metz EN (1983) Phase I trial of homoharringtonine. Cancer Treat Rep 67:801-804
5. O'Brien S, Kantarjian H, Keating M, Beran M, Koller C, Robertson LE, Hester J, Rios MB, Andreeff M, Talpaz M (1995) Homoharringtonine therapy induces responses in patients with chronic myelogenous leukemia in late chronic phase. Blood 86:3322-3326
6. Quintas-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Estrov Z, Giles F, Murgo A, Ladie N, Verstovsek S, Cortes J (2007) Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy. Cancer 109:248-255. doi: 10.1002/cncr.22398
7. Stewart JA, Krakoff IH (1985) Homoharringtonine: a phase I evaluation. Invest New Drugs 3:279-286
8. Gurel G, Blaha G, Moore PB, Steitz TA (2009) U2504 determines the species specificity of the A-site cleft antibiotics: the structures of tiamulin, homoharringtonine, and bruceantin bound to the ribosome. J Mol Biol 389:146-156. doi: 10.1016/j.jmb.2009.04.005
9. Cai Z, Lin M, Wuchter C, Ruppert V, Dorken B, Ludwig WD, Karawajew L (2001) Apoptotic response to homoharringtonine in human wt p53 leukemic cells is independent of reactive oxygen species generation and implicates Bax translocation, mitochondrial cytochrome c release and caspase activation. Leukemia 15:567-574
10. Robert F, Carrier M, Rawe S, Chen S, Lowe S, Pelletier J (2009) Altering chemosensitivity by modulating translation elongation. PLoS ONE 4:e5428. doi: 10.1371/journal.pone.0005428
11. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M (2001) Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 344:1038-1042. doi: 10.1056/nejm200104053441402
12. Kantarjian H, Shah NP, Hochhaus A, Cortes J, Shah S, Ayala M, Moiraghi B, Shen Z, Mayer J, Pasquini R, Nakamae H, Huguet F, Boque C, Chuah C, Bleickardt E, Bradley-Garelik MB, Zhu C, Szatrowski T, Shapiro D, Baccarani M (2010) Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 362:2260-2270. doi: 10.1056/NEJMoa1002315
13. O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ (2003) Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 348:994-1004. doi: 10.1056/NEJMoa022457
14. Saglio G, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Lobo C, Pasquini R, Clark RE, Hochhaus A, Hughes TP, Gallagher N, Hoenekopp A, Dong M, Haque A, Larson RA, Kantarjian HM (2010) Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med 362:2251-2259. doi: 10.1056/NEJMoa0912614
15. Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Muller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA (2009) Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia 23:1054-1061. doi: 10.1038/leu.2009.38
16. Allan EK, Holyoake TL, Craig AR, Jorgensen HG (2011) Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem/progenitor cells. Leukemia 25:985-994. doi: 10.1038/leu.2011.55
17. Nanda N, Cortes C, Lipton J, Rea D, Digumarti R, Chuah C, Benichou AC, Craig A, Michallet M, Nicolini F (2011) Treatment of chronic phase (CP) chronic myeloid leukemia (CML) patients who harbor the BCR-ABL T315I mutation with subcutaneous omacetaxine results in improved survival compared to historical data. Haematologica 96:422-423 (abstract 1012)
18. Cortes-Franco J, Raghunadharao D, Parikh P, Wetzler M, Lipton JH, Jones D, Hochhaus A, Kantarjian HM, Craig AR, Benichou A-C, Humphriss E, Nicolini FE (2009) Safety and efficacy of subcutaneous-administered omacetaxine mepesuccinate in chronic myeloid leukemia (CML) patients who are resistant or intolerant to two or more tyrosine kinase inhibitors - results of a multicenter phase 2/3 study. Blood 114:861 (ASH Annual Meeting Abstracts)
19. Cortes JE, Nicolini FE, Wetzler M, Lipton JH, Akard LP, Craig A, Nanda N, Dial C, Benichou A-C, Cairati K, Baccarani M, Kennealey GT, Kantarjian HM (2011) Subcutaneous omacetaxine in chronic or accelerated chronic myeloid leukemia resistant to two or more tyrosine-kinase inhibitors including imatinib. Blood 118:3761 (ASH Annual Meeting Abstracts)
20. Ni D, Ho DH, Vijjeswarapu M, Felix E, Rhea PR, Newman RA (2003) Metabolism of homoharringtonine, a cytotoxic component of the evergreen plant Cephalotaxus harringtonia. J Exp Ther Oncol 3:47-52
21. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
22. Cheson BD, Bennett JM, Kopecky KJ, Buchner T, Willman CL, Estey EH, Schiffer CA, Doehner H, Tallman MS, Lister TA, Lo-Coco F, Willemze R, Biondi A, Hiddemann W, Larson RA, Lowenberg B, Sanz MA, Head DR, Ohno R, Bloomfield CD (2003) Revised recommendations of the International Working Group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642-4649. doi: 10.1200/jco.2003.04.036
23. Cheson BD, Greenberg PL, Bennett JM, Lowenberg B, Wijermans PW, Nimer SD, Pinto A, Beran M, de Witte TM, Stone RM, Mittelman M, Sanz GF, Gore SD, Schiffer CA, Kantarjian H (2006) Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 108:419-425. doi: 10.1182/blood-2005-10-4149
24. Center for Drug Evaluation and Research. Application no. NDA 21-335: medical review. Available at: http://www.accessdata.fda.gov/drugsatfda-docs/nda/ 2001/21-335-Gleevec-medr-P1.pdf. Accessed 30 May 2012
25. Savaraj N, Lu K, Dimery I, Feun LG, Burgess M, Keating M, Loo TL (1986) Clinical pharmacology of homoharringtonine. Cancer Treat Rep 70:1403-1407
26. Yinjun L, Jie J, Weilai X, Xiangming T (2004) Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP). Am J Hematol 76:199-204. doi: 10.1002/ajh.20100
27. Savaraj N, Feun LG, Lu K, Leavens M, Moser R, Fields WS, Loo TL (1987) Central nervous system (CNS) penetration of homoharringtonine (HHT). J Neurooncol 5:77-81